SCHEMBL3473642

SCHEMBL3473642

CCCCCCCCCCCCn1c2nc(=O)[nH]c(=O)c-2nc2cc3cc(C)c(C)cc3cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.58
KMT2A Q03164 8/20 0.58
USP2 O75604 5/20 0.58
KDM4E B2RXH2 4/20 0.58
MAPT P10636 3/20 0.58
HTT P42858 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
RXFP1 Q9HBX9 2/20 0.58
IDO1 P14902 1/20 0.58
HAT1 O14929 4/20 0.51
RBBP7 Q16576 4/20 0.51
RECQL P46063 3/20 0.51
CASP1 P29466 2/20 0.51
BRCA1 P38398 2/20 0.51
CASP7 P55210 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TST Q16762 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3475382 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL29959761 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL1046544 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL10337856 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL17746904 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL16476449 0.94 MEN1 (0.65) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL12959329 0.93 MEN1 (0.67) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL3473046 0.93 MEN1 (0.57) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL14335565 0.89 MEN1 (0.68) MEN1KMT2AUSP2KDM4EMAPT
SCHEMBL10250507 0.86 MEN1 (0.53) MEN1KMT2AUSP2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193430-B2 Methods for separating carbon nanotubes THE UNIVERSITY OF CONNECTICUT (US) 2012-06-05 US claimed
US-20100044230-A1 METHODS FOR SEPARATING CARBON NANOTUBES UNIVERSITY OF CONNECTICUT (US) 2010-02-25 US claimed
US-9545584-B2 Fractionating nanomaterials by a liquid multiphase composition THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (US) 2017-01-17 US disclosed
US-20140174991-A1 Fractionating nanomaterials by a liquid multiphase composition NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY (US) 2014-06-26 US disclosed
US-8193430-B2 Methods for separating carbon nanotubes THE UNIVERSITY OF CONNECTICUT (US) 2012-06-05 US disclosed
US-8193430-B2 Methods for separating carbon nanotubes THE UNIVERSITY OF CONNECTICUT (US) 2012-06-05 US disclosed
US-20100044230-A1 METHODS FOR SEPARATING CARBON NANOTUBES UNIVERSITY OF CONNECTICUT (US) 2010-02-25 US disclosed
US-20100044230-A1 METHODS FOR SEPARATING CARBON NANOTUBES UNIVERSITY OF CONNECTICUT (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100044230-A1 METHODS FOR SEPARATING CARBON NANOTUBES FSCN1, TTPA, FLNB MEN1 3231/4885KMT2A 4233/4885USP2 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.